Free Access
J Extra Corpor Technol
Volume 39, Number 4, December 2007
Page(s) 305 - 307
Published online 15 December 2007
  1. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057–68. [CrossRef] [PubMed] [Google Scholar]
  2. Vu T-KH, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991;353:674–7. [CrossRef] [PubMed] [Google Scholar]
  3. Parry MA, Myles T, Tschopp J, Stone SR. Cleavage of the thrombin receptor: identification of potential activators and inactivators. Biochem J. 1996;320:335–41. [CrossRef] [PubMed] [Google Scholar]
  4. Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am. 2007;21:103–13. [CrossRef] [Google Scholar]
  5. Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Proteinaseactivated receptors, targets for kallikrein signaling. J Biol Chem. 2006;281:32095–112. [CrossRef] [Google Scholar]
  6. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P. Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs. 2003;12:209–21. [CrossRef] [PubMed] [Google Scholar]
  7. Moliterno DJ. Results of a Multinational Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention. American College of Cardiology Meeting, New Orleans, LA, March 24, 2007. [Google Scholar]
  8. Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA. 1999;96:12257–62. [CrossRef] [PubMed] [Google Scholar]
  9. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2:1289–91. [CrossRef] [Google Scholar]
  10. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640–5. [CrossRef] [Google Scholar]
  11. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation. 1992;86:II405–9. [PubMed] [Google Scholar]
  12. Ferraris VA, Ferraris SP, Singh A, et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg. 1998;65:352–8. [CrossRef] [Google Scholar]
  13. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998;116:716–30. [CrossRef] [Google Scholar]
  14. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: Actions mediated via the proteaseactivated receptor 1. J Thorac Cardiovasc Surg. 2000;120:370–8. [CrossRef] [Google Scholar]
  15. Day JR, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation. 2004;110:2597–600. [CrossRef] [PubMed] [Google Scholar]
  16. Khan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Sellke FW. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg. 2005;79:1545–50. [CrossRef] [Google Scholar]
  17. Poston RS, White C, Gu J, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg. 2006;81:104–10. [CrossRef] [Google Scholar]
  18. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442–8. [CrossRef] [Google Scholar]
  19. Jurk K, Jahn UR, Van AH, et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost. 2004;91:334–44. [CrossRef] [PubMed] [Google Scholar]
  20. Day JRS, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2006;131:21–7. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.